NASDAQ · TXG

10x Genomics, Inc.

$46.27 -$1.79 (-3.72%) 1D After hours

Key Metrics

$6.10B
Market cap
P/E · TTM
$638.78M
Revenue · TTM
−$22.66M
Net income
EPS · TTM $-0.18
Dividend yield
Free cash flow $122.18M
Beta · 1Y 2.31
EBITDA · TTM $18.89M
Gross margin 69.6%

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 27
    Money has been moving out of its sector (Technology).

    Technology has run -4.1 points vs SPY over four weeks, ranking 8→2→11→7 of 11 sectors — this stock trades inside that current.

    RECEIPT: ROTATION MAP, LIVE ↗
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 18.6 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • Jul 9
    The stock moved +15.0% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Jul 9
  • Mar 16
    From its Mar 2 high, the share price fell 28%.

    Peak close $23.14 on Mar 2; trough close $16.69 on Mar 16. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -28%
  • Feb 26
    The stock moved +12.6% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Feb 26

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$6.10B
Enterprise value
Shares outstanding127.0M
52-wk range$11.16 – $49.50
Avg volume · 20D1.7M
Net cash
Book value / share$6.64
IndustryLaboratory Analytical Instruments
ExchangeNASDAQ
About 10x Genomics, Inc.
IPO dateSep 12, 2019
Employees1178

10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E
P/S9.55
P/FCF49.94
EV/EBITDA
EV/Sales
Graham №

Profitability

Gross 69.6%
Operating -3.0%
Net -3.5%
FCF 19.1%
ROE / ROIC -3.0% · -3.0%

Financial Health

Current ratio5.90
Quick ratio5.42
Debt / equity
Debt / EBITDA
Net cash
Working capital$556.14M

Cash Flow · TTM

Operating CF $127.82M
Capex −$5.64M
Free cash flow $122.18M
Buybacks
Dividends paid
Shareholder yield

Piotroski F-Score

4 / 9
Middling fundamentals · 4 of 9 signals passing

Altman Z-Score

17.3
Safe zone (> 2.99) · bankruptcy risk negligible

Graham Number vs Price

Requires positive earnings and book value
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings